Cardio Diagnostics Holdings Inc CDIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges
-
Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City
-
Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026
Trading Information
- Previous Close Price
- $1.75
- Day Range
- $1.72–1.78
- 52-Week Range
- $0.97–7.91
- Bid/Ask
- $1.76 / $1.78
- Shares Outstanding
- 2.96M
- Market Cap
- $5.24M
- Volume/Avg
- 9,476 / 55,657
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 284.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.cdio.ai
Valuation
|
Metric
|
CDIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.70 |
Price/Sales | 284.04 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CDIO
|
|---|---|
Quick Ratio | 15.56 |
Current Ratio | 17.15 |
Interest Coverage | −525.07 |
Quick Ratio
CDIO
Profitability
|
Metric
|
CDIO
|
|---|---|
Return on Assets (Normalized) | −71.69% |
Return on Equity (Normalized) | −77.36% |
Return on Invested Capital (Normalized) | −72.46% |
Return on Assets
CDIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|r$>^xT | LOCK|>BgjW | $123B | |||
| Moderna Inc
MRNA
| LOCK|Grr>WzB | LOCK|lmZ | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|nHm<#h | LOCK|t<ZW | $78B | |||
| argenx SE ADR
ARGX
| LOCK|<d$x<Pd | LOCK|f# | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>$ZQv%M | LOCK|#&@ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#S^^g&L | LOCK|n?#Fn | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Yz@<F<@% | LOCK|D?#J | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|?mDfF% | LOCK|wW> | $22B | |||
| Incyte Corp
INCY
| LOCK|&#MhVM | LOCK|Vl | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|nln^d#? | LOCK|Tw | $14B |
United States